{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:57:10Z","timestamp":1787317030872,"version":"build-2736575974"},"reference-count":135,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2R24AI13661806"],"award-info":[{"award-number":["2R24AI13661806"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Background: Dolutegravir (DTG) is a cornerstone of global antiretroviral (ARV) therapy (ART) due to its high efficacy and favorable tolerability. However, limited data exist regarding the risk of emergent integrase strand transfer inhibitor (INSTI) drug-resistance mutations (DRMs) in individuals receiving DTG-containing ART. Methods: We performed a PubMed search using the term \u201cDolutegravir\u201d, last updated 18 December 2023, to estimate the prevalence of VF with emergent INSTI DRMs in people living with HIV (PLWH) without previous VF on an INSTI who received DTG-containing ART. Results: Of 2131 retrieved records, 43 clinical trials, 39 cohorts, and 6 cross-sectional studies provided data across 6 clinical scenarios based on ART history, virological status, and co-administered ARVs: (1) ART-na\u00efve PLWH receiving DTG plus two NRTIs; (2) ART-na\u00efve PLWH receiving DTG plus lamivudine; (3) ART-experienced PLWH with VF on a previous regimen receiving DTG plus two NRTIs; (4) ART-experienced PLWH with virological suppression receiving DTG plus two NRTIs; (5) ART-experienced PLWH with virological suppression receiving DTG and a second ARV; and (6) ART-experienced PLWH with virological suppression receiving DTG monotherapy. The median proportion of PLWH in clinical trials with emergent INSTI DRMs was 1.5% for scenario 3 and 3.4% for scenario 6. In the remaining four trial scenarios, VF prevalence with emergent INSTI DRMs was \u22640.1%. Data from cohort studies minimally influenced prevalence estimates from clinical trials, whereas cross-sectional studies yielded prevalence data lacking denominator details. Conclusions: In clinical trials, the prevalence of VF with emergent INSTI DRMs in PLWH receiving DTG-containing regimens has been low. Novel approaches are required to assess VF prevalence with emergent INSTI DRMs in PLWH receiving DTG in real-world settings.<\/jats:p>","DOI":"10.3390\/v16030399","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T08:03:47Z","timestamp":1709539427000},"page":"399","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review"],"prefix":"10.3390","volume":"16","author":[{"given":"Carolyn","family":"Chu","sequence":"first","affiliation":[{"name":"Department of Family and Community Medicine, University of California San Francisco, San Francisco, CA 94110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiming","family":"Tao","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3531-7780","authenticated-orcid":false,"given":"Vinie","family":"Kouamou","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare 00263, Zimbabwe"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4111-7072","authenticated-orcid":false,"given":"Ava","family":"Avalos","sequence":"additional","affiliation":[{"name":"Careena Center for Health, Gaborone, Botswana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4210-509X","authenticated-orcid":false,"given":"Jake","family":"Scott","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip M.","family":"Grant","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Yon","family":"Rhee","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne M.","family":"McCluskey","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Jordan","sequence":"additional","affiliation":[{"name":"Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, MA 02111, USA"},{"name":"Collaboratory for Emerging Infectious Diseases and Response (CEIDR), Tufts University, Medford, MA 02155, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Morgan","sequence":"additional","affiliation":[{"name":"School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2513-2643","authenticated-orcid":false,"given":"Robert W.","family":"Shafer","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,4]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2022, August 17). Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach. Available online: https:\/\/www.who.int\/publications-detail-redirect\/9789240031593."},{"key":"ref_2","unstructured":"Clinton Health Access Initiative (2023). The State of HIV Treatment, Testing, and Prevention in Low- and Middle-Income Countries, Clinton Health Access Initiative. HIV Market Report 2023."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Tao, K., Rhee, S.-Y., Chu, C., Avalos, A., Ahluwalia, A.K., Gupta, R.K., Jordan, M.R., and Shafer, R.W. (2023). Treatment Emergent Dolutegravir Resistance Mutations in Individuals Na\u00efve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review. Viruses, 15.","DOI":"10.3390\/v15091932"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jac\/dkz417","article-title":"Integrase Strand Transfer Inhibitor (INSTI)-Resistance Mutations for the Surveillance of Transmitted HIV-1 Drug Resistance","volume":"75","author":"Tzou","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1473-3099(11)70290-0","article-title":"Once Daily Dolutegravir (S\/GSK1349572) in Combination Therapy in Antiretroviral-Naive Adults with HIV: Planned Interim 48 Week Results from SPRING-1, a Dose-Ranging, Randomised, Phase 2b Trial","volume":"12","author":"Maggiolo","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1097\/QAD.0b013e3283612419","article-title":"Dolutegravir in Antiretroviral-Naive Adults with HIV-1: 96-Week Results from a Randomized Dose-Ranging Study","volume":"27","author":"Stellbrink","year":"2013","journal-title":"AIDS"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-Daily Dolutegravir versus Raltegravir in Antiretroviral-Naive Adults with HIV-1 Infection: 48 Week Results from the Randomised, Double-Blind, Non-Inferiority SPRING-2 Study","volume":"381","author":"Raffi","year":"2013","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Once-Daily Dolutegravir versus Twice-Daily Raltegravir in Antiretroviral-Naive Adults with HIV-1 Infection (SPRING-2 Study): 96 Week Results from a Randomised, Double-Blind, Non-Inferiority Trial","volume":"13","author":"Raffi","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus Abacavir\u2013Lamivudine for the Treatment of HIV-1 Infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/QAI.0000000000000790","article-title":"Brief Report: Dolutegravir Plus Abacavir\/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial","volume":"70","author":"Walmsley","year":"2015","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-Daily Dolutegravir versus Darunavir plus Ritonavir in Antiretroviral-Naive Adults with HIV-1 Infection (FLAMINGO): 48 Week Results from the Randomised Open-Label Phase 3b Study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3018(15)00027-2","article-title":"Once-Daily Dolutegravir versus Darunavir plus Ritonavir for Treatment-Naive Adults with HIV-1 Infection (FLAMINGO): 96 Week Results from a Randomised, Open-Label, Phase 3b Study","volume":"2","author":"Molina","year":"2015","journal-title":"Lancet HIV"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e536","DOI":"10.1016\/S2352-3018(17)30095-4","article-title":"Fixed-Dose Combination Dolutegravir, Abacavir, and Lamivudine versus Ritonavir-Boosted Atazanavir plus Tenofovir Disoproxil Fumarate and Emtricitabine in Previously Untreated Women with HIV-1 Infection (ARIA): Week 48 Results from a Randomised, Open-Label, Non-Inferiority, Phase 3b Study","volume":"4","author":"Orrell","year":"2017","journal-title":"Lancet HIV"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV","volume":"381","author":"Venter","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e666","DOI":"10.1016\/S2352-3018(20)30241-1","article-title":"Dolutegravir with Emtricitabine and Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate versus Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection (ADVANCE): Week 96 Results from a Randomised, Phase 3, Non-Inferiority Trial","volume":"7","author":"Venter","year":"2020","journal-title":"Lancet HIV"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e1008","DOI":"10.1093\/cid\/ciab086","article-title":"Participants on Dolutegravir Resuppress Human Immunodeficiency Virus RNA After Virologic Failure: Updated Data from the ADVANCE Trial","volume":"73","author":"Pepperrell","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJMoa1904340","article-title":"Dolutegravir-Based or Low-Dose Efavirenz\u2013Based Regimen for the Treatment of HIV-1","volume":"381","author":"Kouanfack","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e677","DOI":"10.1016\/S2352-3018(20)30238-1","article-title":"Dolutegravir-Based and Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-1 Infection (NAMSAL): Week 96 Results from a Two-Group, Multicentre, Randomised, Open Label, Phase 3 Non-Inferiority Trial in Cameroon","volume":"7","author":"Calmy","year":"2020","journal-title":"Lancet HIV"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Dolutegravir with Emtricitabine and Tenofovir Alafenamide, for Initial Treatment of HIV-1 Infection (GS-US-380\u20131490): A Randomised, Double-Blind, Multicentre, Phase 3, Non-Inferiority Trial","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2352-3018(17)30016-4","article-title":"Bictegravir versus Dolutegravir, Each with Emtricitabine and Tenofovir Alafenamide, for Initial Treatment of HIV-1 Infection: A Randomised, Double-Blind, Phase 2 Trial","volume":"4","author":"Sax","year":"2017","journal-title":"Lancet HIV"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/S2352-3018(19)30080-3","article-title":"Co-Formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Dolutegravir with Emtricitabine and Tenofovir Alafenamide for Initial Treatment of HIV-1 Infection: Week 96 Results from a Randomised, Double-Blind, Multicentre, Phase 3, Non-Inferiority Trial","volume":"6","author":"Stellbrink","year":"2019","journal-title":"Lancet HIV"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Dolutegravir, Abacavir, and Lamivudine for Initial Treatment of HIV-1 Infection (GS-US-380-1489): A Double-Blind, Multicentre, Phase 3, Randomised Controlled Non-Inferiority Trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3018(19)30077-3","article-title":"Bictegravir Combined with Emtricitabine and Tenofovir Alafenamide versus Dolutegravir, Abacavir, and Lamivudine for Initial Treatment of HIV-1 Infection: Week 96 Results from a Randomised, Double-Blind, Multicentre, Phase 3, Non-Inferiority Trial","volume":"6","author":"Wohl","year":"2019","journal-title":"Lancet HIV"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"ofab595","DOI":"10.1093\/ofid\/ofab595","article-title":"Darunavir\/Cobicistat\/Emtricitabine\/Tenofovir Alafenamide Versus Dolutegravir\/Abacavir\/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC\/RIS-57)","volume":"9","author":"Podzamczer","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus Lamivudine versus Dolutegravir plus Tenofovir Disoproxil Fumarate and Emtricitabine in Antiretroviral-Naive Adults with HIV-1 Infection (GEMINI-1 and GEMINI-2): Week 48 Results from Two Multicentre, Double-Blind, Randomised, Non-Inferiority, Phase 3 Trials","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/QAI.0000000000002275","article-title":"Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment\u2013Naive Adults with HIV-1 Infection: 96-Week Results from the GEMINI-1 and GEMINI-2 Randomized Clinical Trials","volume":"83","author":"Cahn","year":"2020","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAD.0000000000003070","article-title":"Three-Year Durable Efficacy of Dolutegravir plus Lamivudine in Antiretroviral Therapy\u2014Naive Adults with HIV-1 Infection","volume":"36","author":"Cahn","year":"2022","journal-title":"AIDS"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S0140-6736(21)00314-7","article-title":"Efficacy and Safety of Dolutegravir with Emtricitabine and Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate, and Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate HIV Antiretroviral Therapy Regimens Started in Pregnancy (IMPAACT 2010\/VESTED): A Multicentre, Open-Label, Randomised, Controlled, Phase 3 Trial","volume":"397","author":"Lockman","year":"2021","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e363","DOI":"10.1016\/S2352-3018(23)00061-9","article-title":"Efficacy and Safety of Three Antiretroviral Therapy Regimens Started in Pregnancy up to 50 Weeks Post Partum: A Multicentre, Open-Label, Randomised, Controlled, Phase 3 Trial","volume":"10","author":"Chinula","year":"2023","journal-title":"Lancet HIV"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1093\/jac\/dkac207","article-title":"Once-Daily Dolutegravir versus Darunavir plus Cobicistat in Adults at the Time of Primary HIV-1 Infection: The OPTIPRIM2-ANRS 169 Randomized, Open-Label, Phase 3 Trial","volume":"77","author":"Bauer","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e640","DOI":"10.1016\/S2352-3018(23)00151-0","article-title":"Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Dolutegravir, Emtricitabine, and Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 and Hepatitis B Coinfection (ALLIANCE): A Double-Blind, Multicentre, Randomised Controlled, Phase 3 Non-Inferiority Trial","volume":"10","author":"Avihingsanon","year":"2023","journal-title":"Lancet HIV"},{"key":"ref_33","first-page":"549","article-title":"Dolutegravir-Based Antiretroviral Therapy for Patients Coinfected with Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-Label, Randomized Trial","volume":"70","author":"Dooley","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3018(23)00081-4","article-title":"Standard-Dose versus Double-Dose Dolutegravir in HIV-Associated Tuberculosis in South Africa (RADIANT-TB): A Phase 2, Non-Comparative, Randomised Controlled Trial","volume":"10","author":"Griesel","year":"2023","journal-title":"Lancet HIV"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1097\/QAD.0000000000001931","article-title":"Evaluating Outcomes of Mother\u2013Infant Pairs Using Dolutegravir for HIV Treatment during Pregnancy","volume":"32","author":"Grayhack","year":"2018","journal-title":"AIDS"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"ofaa316","DOI":"10.1093\/ofid\/ofaa316","article-title":"Virological Failure and Acquired Genotypic Resistance Associated with Contemporary Antiretroviral Treatment Regimens","volume":"7","author":"Rhee","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e25227","DOI":"10.1002\/jia2.25227","article-title":"Effectiveness of Dolutegravir-Based Regimens as Either First-Line or Switch Antiretroviral Therapy: Data from the Icona Cohort","volume":"22","author":"Mondi","year":"2019","journal-title":"J. Int. AIDS Soc."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"104534","DOI":"10.1016\/j.jcv.2020.104534","article-title":"Evaluation of Virological Response and Resistance Profile in HIV-1 Infected Patients Starting a First-Line Integrase Inhibitor-Based Regimen in Clinical Settings","volume":"130","author":"Armenia","year":"2020","journal-title":"J. Clin. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/jac\/dkad102","article-title":"Effectiveness and Tolerability of Dolutegravir\/Lamivudine for the Treatment of HIV-1 Infection in Clinical Practice","volume":"78","author":"Alejos","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.3346\/jkms.2020.35.e235","article-title":"Similar Durability of Two Single Tablet Regimens, Dolutegravir\/Abacavir\/Lamivudine and Elvitegravir\/Cobicistat\/Tenofovir\/Emtricitabine: Single Center Experience","volume":"35","author":"Chin","year":"2020","journal-title":"J. Korean Med. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"ofad321","DOI":"10.1093\/ofid\/ofad321","article-title":"Transitioning to Dolutegravir in a Programmatic Setting: Virological Outcomes and Associated Factors Among Treatment-Naive Patients with HIV-1 in the Kilombero and Ulanga Antiretroviral Cohort in Rural Tanzania","volume":"10","author":"Ntamatungiro","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Diaz, R.S., Hunter, J.R., Camargo, M., Dias, D., Galinskas, J., Nassar, I., De Lima, I.B., Caldeira, D.B., Sucupira, M.C., and Schechter, M. (2023). Dolutegravir-Associated Resistance Mutations after First-Line Treatment Failure in Brazil. BMC Infect. Dis., 23.","DOI":"10.1186\/s12879-023-08288-8"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1093\/cid\/cix1083","article-title":"ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)\u2013Infected Participants with HIV-1 RNA <500000 Copies\/mL","volume":"66","author":"Taiwo","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/jac\/dky564","article-title":"Dolutegravir plus Lamivudine for Initial Treatment of HIV-1-Infected Participants with HIV-1 RNA <500\u2009000 Copies\/mL: Week 48 Outcomes from ACTG 5353","volume":"74","author":"Nyaku","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1097\/QAD.0000000000002979","article-title":"Dolutegravir\/Lamivudine as a First-Line Regimen in a Test-and-Treat Setting for Newly Diagnosed People Living with HIV","volume":"35","author":"Rolle","year":"2021","journal-title":"AIDS"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"ofad101","DOI":"10.1093\/ofid\/ofad101","article-title":"Sustained Virologic Suppression with Dolutegravir\/Lamivudine in a Test-and-Treat Setting through 48 Weeks","volume":"10","author":"Rolle","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Hidalgo-Tenorio, C., Pasquau, J., Vinuesa, D., Ferra, S., Terr\u00f3n, A., SanJoaqu\u00edn, I., Payeras, A., Mart\u00ednez, O.J., L\u00f3pez-Ruz, M.\u00c1., and Omar, M. (2022). DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks). Viruses, 14.","DOI":"10.20944\/preprints202202.0134.v1"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"21678","DOI":"10.7448\/IAS.20.01.21678","article-title":"Dolutegravir\u2013Lamivudine as Initial Therapy in HIV-1 Infected, ARV-Naive Patients, 48-Week Results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) Study","volume":"20","author":"Cahn","year":"2017","journal-title":"J. Int. AIDS Soc."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Cabello-Ubeda, A., de Quir\u00f3s, J.C.L.B., Carbonero, L.M., Sanz, J., Vergas, J., Mena, \u00c1., Torralba, M., Segurado, M.H., Pinto, A., and Tejerina, F. (2022). 48-Week Effectiveness and Tolerability of Dolutegravir (DTG) + Lamivudine (3TC) in Antiretroviral-Na\u00efve Adults Living with HIV: A Multicenter Real-Life Cohort. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0277606"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e31100","DOI":"10.1097\/MD.0000000000031100","article-title":"Real-World Efficacy and Safety of Dolutegravir plus Lamivudine versus Tenofovir plus Lamivudine and Efavirenz in ART-Na\u00efve HIV-1-Infected Adults","volume":"101","author":"Li","year":"2022","journal-title":"Medicine"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus Raltegravir in Antiretroviral-Experienced, Integrase-Inhibitor-Naive Adults with HIV: Week 48 Results from the Randomised, Double-Blind, Non-Inferiority SAILING Study","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet"},{"key":"ref_52","unstructured":"Underwood, M. (2015, January 3\u20135). Euro Resistance Wk: Resistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naive Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762). Proceedings of the 13th European HIV & Hepatitis Workshop, Barcelona, Spain."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1473-3099(19)30036-2","article-title":"Dolutegravir versus Ritonavir-Boosted Lopinavir Both with Dual Nucleoside Reverse Transcriptase Inhibitor Therapy in Adults with HIV-1 Infection in Whom First-Line Therapy Has Failed (DAWNING): An Open-Label, Non-Inferiority, Phase 3b Trial","volume":"19","author":"Aboud","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e0164321","DOI":"10.1128\/AAC.01643-21","article-title":"Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study","volume":"66","author":"Underwood","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa2101609","article-title":"Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV","volume":"385","author":"Paton","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1016\/S2352-3018(22)00092-3","article-title":"Efficacy and Safety of Dolutegravir or Darunavir in Combination with Lamivudine plus Either Zidovudine or Tenofovir for Second-Line Treatment of HIV Infection (NADIA): Week 96 Results from a Prospective, Multicentre, Open-Label, Factorial, Randomised, Non-Inferiority Trial","volume":"9","author":"Paton","year":"2022","journal-title":"Lancet HIV"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1097\/QAD.0000000000002936","article-title":"Virologic Efficacy of Tenofovir, Lamivudine and Dolutegravir as Second-Line Antiretroviral Therapy in Adults Failing a Tenofovir-Based First-Line Regimen","volume":"35","author":"Keene","year":"2021","journal-title":"AIDS"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/QAI.0000000000003157","article-title":"Recycling Tenofovir in Second-Line Antiretroviral Treatment with Dolutegravir: Outcomes and Viral Load Trajectories to 72 Weeks","volume":"92","author":"Keene","year":"2023","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1093\/cid\/ciad023","article-title":"Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial","volume":"76","author":"Zhao","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1097\/INF.0000000000000848","article-title":"Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-Experienced HIV-1 Infected Adolescents: Forty-Eight-Week Results from IMPAACT P1093","volume":"34","author":"Viani","year":"2015","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/jpids\/piy139","article-title":"Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents with Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study","volume":"9","author":"Viani","year":"2020","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e0164521","DOI":"10.1128\/AAC.01645-21","article-title":"Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study","volume":"66","author":"Vavro","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa2108793","article-title":"Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children","volume":"385","author":"Turkova","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/S2352-3018(22)00163-1","article-title":"Once-Daily Dolutegravir-Based Antiretroviral Therapy in Infants and Children Living with HIV from Age 4 Weeks: Results from the below 14 Kg Cohort in the Randomised ODYSSEY Trial","volume":"9","author":"Amuge","year":"2022","journal-title":"Lancet HIV"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/QAD.0000000000001494","article-title":"Emergent Drug Resistance with Integrase Strand Transfer Inhibitor-Based Regimens","volume":"31","author":"Lepik","year":"2017","journal-title":"AIDS"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ijantimicag.2018.01.009","article-title":"Effect of Dolutegravir in Combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on People Living with HIV Who Have Pre-Existing NRTI Mutations","volume":"51","author":"Carlander","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e544","DOI":"10.1016\/S2352-3018(22)00136-9","article-title":"Viral Suppression and HIV-1 Drug Resistance 1 Year after Pragmatic Transitioning to Dolutegravir First-Line Therapy in Malawi: A Prospective Cohort Study","volume":"9","author":"Schramm","year":"2022","journal-title":"Lancet HIV"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/hiv.13189","article-title":"Viral Suppression after Transition from Nonnucleoside Reverse Transcriptase Inhibitor- to Dolutegravir-Based Antiretroviral Therapy: A Prospective Cohort Study in Lesotho (DO-REAL Study)","volume":"23","author":"Brown","year":"2022","journal-title":"HIV Med."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Semengue, E.N.J., Fokam, J., Etame, N.-K., Molimbou, E., Chenwi, C.A., Takou, D., Mossiang, L., Meledie, A.P., Yagai, B., and Nka, A.D. (2023). Dolutegravir-Based Regimen Ensures High Virological Success despite Prior Exposure to Efavirenz-Based First-LINE ART in Cameroon: An Evidence of a Successful Transition Model. Viruses, 15.","DOI":"10.3390\/v15010018"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"ofac148","DOI":"10.1093\/ofid\/ofac148","article-title":"Dolutegravir Resistance in Malawi\u2019s National HIV Treatment Program","volume":"9","author":"Chipungu","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1093\/jac\/dkad195","article-title":"Limited Emergence of Resistance to Integrase Strand Transfer Inhibitors (INSTIs) in ART-Experienced Participants Failing Dolutegravir-Based Antiretroviral Therapy: A Cross-Sectional Analysis of a Northeast Nigerian Cohort","volume":"78","author":"Abdullahi","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/jac\/dkad010","article-title":"Emerging Integrase Strand Transfer Inhibitor Drug Resistance Mutations among Children and Adults on ART in Tanzania: Findings from a National Representative HIV Drug Resistance Survey","volume":"78","author":"Kamori","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/jpids\/piad040","article-title":"Factors Associated with Viral Suppression and Drug Resistance in Children and Adolescents Living with HIV in Care and Treatment Programs in Southern Tanzania","volume":"12","author":"Khamadi","year":"2023","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"20493","DOI":"10.1038\/s41598-023-47795-1","article-title":"High Viral Suppression and Detection of Dolutegravir-Resistance Associated Mutations in Treatment-Experienced Tanzanian Adults Living with HIV-1 in Dar Es Salaam","volume":"13","author":"Bwire","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1097\/QAD.0000000000001675","article-title":"Switching from a Ritonavir-Boosted Protease Inhibitor to a Dolutegravir-Based Regimen for Maintenance of HIV Viral Suppression in Patients with High Cardiovascular Risk","volume":"31","author":"Gatell","year":"2017","journal-title":"AIDS"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/cid\/ciy505","article-title":"Immediate Versus Deferred Switching from a Boosted Protease Inhibitor\u2013Based Regimen to a Dolutegravir-Based Regimen in Virologically Suppressed Patients with High Cardiovascular Risk or Age \u226550 Years: Final 96-Week Results of the NEAT022 Study","volume":"68","author":"Gatell","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3851\/IMP3166","article-title":"Dolutegravir\/Abacavir\/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study","volume":"22","author":"Trottier","year":"2017","journal-title":"Antivir. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa2210005","article-title":"Second-Line Switch to Dolutegravir for Treatment of HIV Infection","volume":"388","author":"Ombajo","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"ofz330","DOI":"10.1093\/ofid\/ofz330","article-title":"Impact of the M184V\/I Mutation on the Efficacy of Abacavir\/Lamivudine\/Dolutegravir Therapy in HIV Treatment-Experienced Patients","volume":"6","author":"Olearo","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/jac\/dkaa019","article-title":"M184V\/I Does Not Impact the Efficacy of Abacavir\/Lamivudine\/Dolutegravir Use as Switch Therapy in Virologically Suppressed Patients","volume":"75","author":"Jary","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/jac\/dkab429","article-title":"Virological Outcomes with Dolutegravir plus Either Lamivudine or Two NRTIs as Switch Strategies: A Multi-Cohort Study","volume":"77","author":"Borghetti","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and Safety of Switching to Dolutegravir\/Lamivudine Fixed-Dose 2-Drug Regimen vs. Continuing a Tenofovir Alafenamide\u2013Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living with Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study","volume":"71","author":"Ajana","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/ciac036","article-title":"Efficacy and Safety of Switching to Dolutegravir\/Lamivudine Versus Continuing a Tenofovir Alafenamide\u2013Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living with Human Immunodeficiency Virus Type 1: Results through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial","volume":"75","author":"Osiyemi","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/cid\/ciac130","article-title":"Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir\/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living with Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results from the Phase 3, Noninferiority SALSA Randomized Trial","volume":"76","author":"Llibre","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/S2352-3018(21)00100-4","article-title":"Efficacy and Safety of Switching to Dolutegravir plus Lamivudine versus Continuing Triple Antiretroviral Therapy in Virologically Suppressed Adults with HIV at 48 Weeks (DOLAM): A Randomised Non-Inferiority Trial","volume":"8","author":"Rojas","year":"2021","journal-title":"Lancet HIV"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/jac\/dky467","article-title":"Dolutegravir and Lamivudine Maintenance Therapy in HIV-1 Virologically Suppressed Patients: Results of the ANRS 167 Trial (LAMIDOL)","volume":"74","author":"Joly","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/cid\/cix1131","article-title":"Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial","volume":"66","author":"Taiwo","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"ofac610","DOI":"10.1093\/ofid\/ofac610","article-title":"Long-Term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants with and without Prior Lamivudine Resistance","volume":"9","author":"Montejano","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/jac\/dkaa479","article-title":"Long-Term Efficacy of Dolutegravir plus Lamivudine for Maintenance of HIV Viral Suppression in Adults with and without Historical Resistance to Lamivudine: Week 96 Results of ART-PRO Pilot Study","volume":"76","author":"Montejano","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"De Miguel, R., Rial-Crestelo, D., Dominguez-Dominguez, L., Montejano, R., Esteban-Cantos, A., Aranguren-Rivas, P., Stella-Ascariz, N., Bisbal, O., Bermejo-Plaza, L., and Garcia-Alvarez, M. (2020). Dolutegravir plus Lamivudine for Maintenance of HIV Viral Suppression in Adults with and without Historical Resistance to Lamivudine: 48-Week Results of a Non-Randomized, Pilot Clinical Trial (ART-PRO). EBioMedicine, 55.","DOI":"10.1016\/j.ebiom.2020.102779"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Sculier, D., Wandeler, G., Yerly, S., Marinosci, A., Stoeckle, M., Bernasconi, E., Braun, D.L., Vernazza, P., Cavassini, M., and Buzzi, M. (2020). Efficacy and Safety of Dolutegravir plus Emtricitabine versus Standard ART for the Maintenance of HIV-1 Suppression: 48-Week Results of the Factorial, Randomized, Non-Inferiority SIMPL\u2019HIV Trial. PLoS Med., 17.","DOI":"10.1371\/journal.pmed.1003421"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, Safety, and Tolerability of Dolutegravir-Rilpivirine for the Maintenance of Virological Suppression in Adults with HIV-1: Phase 3, Randomised, Non-Inferiority SWORD-1 and SWORD-2 Studies","volume":"391","author":"Llibre","year":"2018","journal-title":"Lancet"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e576","DOI":"10.1016\/S2352-3018(19)30149-3","article-title":"Efficacy and Safety of Dolutegravir\u2013Rilpivirine for Maintenance of Virological Suppression in Adults with HIV-1: 100-Week Data from the Randomised, Open-Label, Phase 3 SWORD-1 and SWORD-2 Studies","volume":"6","author":"Aboud","year":"2019","journal-title":"Lancet HIV"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/QAI.0000000000002449","article-title":"Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials","volume":"85","author":"Orkin","year":"2020","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"ofaa356","DOI":"10.1093\/ofid\/ofaa356","article-title":"Efficacy and Safety of Switching to Dolutegravir with Boosted Darunavir in Virologically Suppressed Adults with HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study","volume":"7","author":"Spinner","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12981-021-00384-6","article-title":"Virologic Outcomes of Switching to Boosted Darunavir plus Dolutegravir with Respect to History of Drug Resistance","volume":"18","author":"Wolf","year":"2021","journal-title":"AIDS Res. Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"102025","DOI":"10.1016\/j.eclinm.2023.102025","article-title":"Nucleoside\/Nucleotide Reverse Transcriptase Inhibitor Sparing Regimen with Once Daily Integrase Inhibitor plus Boosted Darunavir Is Non-Inferior to Standard of Care in Virologically-Suppressed Children and Adolescents Living with HIV\u2014Week 48 Results of the Randomised SMILE Penta-17-ANRS 152 Clinical Trial","volume":"60","author":"Compagnucci","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/hiv.12506","article-title":"Efficacy and Safety of Dolutegravir and Rilpivirine Dual Therapy as a Simplification Strategy: A Cohort Study","volume":"18","author":"Gantner","year":"2017","journal-title":"HIV Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/jac\/dkz009","article-title":"Virological Efficacy of Dual Therapy with Lamivudine and Dolutegravir in HIV-1-Infected Virologically Suppressed Patients: Long-Term Data from Clinical Practice","volume":"74","author":"Baldin","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1080\/15284336.2019.1628460","article-title":"Dolutegravir plus Rilpivirine as Dual Regimen in Virologically Suppressed HIV-1 Infected Patients in a Clinical Setting","volume":"20","author":"Casado","year":"2019","journal-title":"HIV Res. Clin. Pract."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/QAD.0000000000002188","article-title":"Switch to Dolutegravir and Unboosted Atazanavir in HIV-1 Infected Patients with Undetectable Viral Load and Long Exposure to Antiretroviral Therapy","volume":"33","author":"Castagna","year":"2019","journal-title":"AIDS"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1093\/jac\/dkaa319","article-title":"Simplification to Dual Therapy Containing Lamivudine and Raltegravir or Dolutegravir in HIV-Infected Patients on Virologically Suppressive Antiretroviral Therapy","volume":"75","author":"Calza","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/QAI.0000000000002787","article-title":"Five Years with Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding","volume":"88","author":"Ciccullo","year":"2021","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jac\/dkac362","article-title":"Analysing the Efficacy and Tolerability of Dolutegravir plus Either Rilpivirine or Lamivudine in a Multicentre Cohort of Virologically Suppressed PLWHIV","volume":"78","author":"Ciccullo","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"426","DOI":"10.4314\/ahs.v22i3.46","article-title":"Evaluation of Treatment Efficacy after Switching to Dolutegravir-Lamivudine Dual Therapy in People Living with HIV","volume":"22","author":"Ergen","year":"2022","journal-title":"Afr. Health Sci."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Lee, K.H., Kim, J., Lee, J.A., Kim, C.H., Ahn, J.Y., Jeong, S.J., Ku, N.S., Choi, J.Y., Yeom, J.-S., and Song, Y.G. (2022). Real-World Effectiveness, Tolerability, and Safety of Dolutegravir\/Lamivudine in Korea. Viruses, 14.","DOI":"10.3390\/v14112558"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Maggiolo, F., Gulminetti, R., Pagnucco, L., Digaetano, M., Cervo, A., Valenti, D., Callegaro, A., and Mussini, C. (2022). Long-Term Outcome of Lamivudine\/Dolutegravir Dual Therapy in HIV-Infected, Virologically Suppressed Patients. BMC Infect. Dis., 22.","DOI":"10.1186\/s12879-022-07769-6"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e29252","DOI":"10.1097\/MD.0000000000029252","article-title":"Dolutegravir plus Rilpivirine: Benefits beyond Viral Suppression: DORIPEX Retrospective Study","volume":"101","author":"Troya","year":"2022","journal-title":"Medicine"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/QAD.0000000000003480","article-title":"Real World Use of Dolutegravir Two Drug Regimens","volume":"37","author":"Bowman","year":"2023","journal-title":"AIDS"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Buz\u00f3n, L., Due\u00f1as, C., Pedrero, R., Iribarren, J.A., de los Santos, I., D\u00edaz de Santiago, A., Mor\u00e1n, M.\u00c1., Pousada, G., Moreno, E., and Ferreira, E. (2023). Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic. Viruses, 15.","DOI":"10.3390\/v15020322"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/hiv.13500","article-title":"Three-Year Efficacy of Switching to Dolutegravir plus Lamivudine: A Real-World Study","volume":"24","author":"Palmier","year":"2023","journal-title":"HIV Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1089\/aid.2023.0046","article-title":"Efficacy and Safety of Switching to Dolutegravir\/Lamivudine in Virologically Suppressed People Living with HIV-1 Aged over 65 Years","volume":"40","author":"Calza","year":"2023","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_113","first-page":"2239564","article-title":"Switching to Dolutegravir\/Lamivudine or Bictegravir\/Emtricitabine\/Tenofovir Alafenamide. A Comparative Real-World Study","volume":"24","author":"Knobel","year":"2023","journal-title":"HIV Res. Clin. Pract."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/QAI.0000000000003248","article-title":"Doravirine Plus Integrase Strand Transfer Inhibitors as a 2-Drug Treatment\u2013Switch Strategy in People Living with HIV: The Real-Life DORINI Multicentric Cohort Study","volume":"94","author":"Poliseno","year":"2023","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1016\/S2352-3018(17)30152-2","article-title":"Dolutegravir as Maintenance Monotherapy for HIV (DOMONO): A Phase 2, Randomised Non-Inferiority Trial","volume":"4","author":"Wijting","year":"2017","journal-title":"Lancet HIV"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/infdis\/jiy176","article-title":"HIV-1 Resistance Dynamics in Patients with Virologic Failure to Dolutegravir Maintenance Monotherapy","volume":"218","author":"Wijting","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/hiv.12675","article-title":"Predictors of Virological Failure in HIV-1-Infected Patients Switching to Dolutegravir Maintenance Monotherapy","volume":"20","author":"Wijting","year":"2019","journal-title":"HIV Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1093\/jac\/dky093","article-title":"Dolutegravir-Based Maintenance Monotherapy versus Dual Therapy with Lamivudine: A Planned 24 Week Analysis of the DOLAM Randomized Clinical Trial","volume":"73","author":"Blanco","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/cid\/ciy1131","article-title":"Noninferiority of Simplified Dolutegravir Monotherapy Compared to Continued Combination Antiretroviral Therapy That Was Initiated During Primary Human Immunodeficiency Virus Infection: A Randomized, Controlled, Multisite, Open-Label, Noninferiority Trial","volume":"69","author":"Braun","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/cid\/ciad366","article-title":"Sustained Viral Suppression with Dolutegravir Monotherapy over 192 Weeks in Patients Starting Combination Antiretroviral Therapy during Primary HIV Infection (EARLY-SIMPLIFIED): A Randomized, Controlled, Multi-Site, Non-Inferiority Trial","volume":"77","author":"West","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/cid\/ciy1132","article-title":"Dolutegravir Monotherapy Versus Dolutegravir\/Abacavir\/Lamivudine for Virologically Suppressed People Living with Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial","volume":"69","author":"Hocqueloux","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1093\/jac\/dkw078","article-title":"Dolutegravir Monotherapy in HIV-Infected Patients with Sustained Viral Suppression","volume":"71","author":"Rojas","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3851\/IMP3082","article-title":"Dolutegravir Monotherapy as Treatment De-Escalation in HIV-Infected Adults with Virological Control: DoluMono Cohort Results","volume":"22","author":"Oldenbuettel","year":"2017","journal-title":"Antivir. Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/jac\/dkz478","article-title":"Long-Term Follow-up of HIV-Infected Patients on Dolutegravir Monotherapy","volume":"75","author":"Tebano","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S1473-3099(16)30469-8","article-title":"Occult HIV-1 Drug Resistance to Thymidine Analogues Following Failure of First-Line Tenofovir Combined with a Cytosine Analogue and Nevirapine or Efavirenz in Sub Saharan Africa: A Retrospective Multi-Centre Cohort Study","volume":"17","author":"Gregson","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_126","unstructured":"World Health Organization (2021). HIV Drug Resistance Report 2021, WHO."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e071283","DOI":"10.1136\/bmjopen-2022-071283","article-title":"Prior Exposure to Antiretroviral Therapy among Adult Patients Presenting for HIV Treatment Initiation or Reinitiation in Sub-Saharan Africa: A Systematic Review","volume":"13","author":"Benade","year":"2023","journal-title":"BMJ Open"},{"key":"ref_128","unstructured":"Mulenga, L.B., Fwoloshi, S., Mweemba, A., Siwingwa, M., Sivile, S., Kampamba, D., Engamba, D.C., Mbewe, N., Phiri, H., and Shibemba, A. (2022, January 12\u201316). Dolutegravir with Recycled Nrtis Is Noninferior to Pi-Based Art: Visend Trial. Proceedings of the 29th Conference on Retroviruses and Opportunistic Infections, Virtual."},{"key":"ref_129","unstructured":"Matthews, G., Borok, M., Eriobou, N., Kaplan, R., Kumarasamy, N., Avihingsanon, A., Losso, M.H., Azwa, I.S., Karyana, M., and Dao, S. (2023, January 19\u201322). D2EFT: Dolutegravir and Darunavir Evaluation in Adults Failing First-Line Hiv Therapy. Proceedings of the 30th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA."},{"key":"ref_130","unstructured":"World Health Organization (2022). Sentinel Surveys of Acquired HIV Resistance to Dolutegravir among People Receiving Dolutegravir Containing Antiviral Therapy, WHO."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/infdis\/jiab382","article-title":"Monitoring Emerging Human Immunodeficiency Virus Drug Resistance in Sub-Saharan Africa in the Era of Dolutegravir","volume":"225","author":"Pals","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_132","unstructured":"Bhatt, N., Ismail, N., Magule, C., Hussein, C., Meque, I., Couto, A., Nhangave, A., Muteerwa, A., Bonou, A., and Ramos, A. (2023, January 20\u201322). HIV Drug Resistance Profile in Clients Experiencing Treatment Failure after the Transition Fo a Dolutegravir-Based First-Line Antiretroviral Treatment Regimen in Mozambique [Abstract 51]. Proceedings of the International Workshop on HIV Drug Resistance and Treatment Strategies, Cape Town, South Africa."},{"key":"ref_133","unstructured":"Kalata, N., Pals, S., Bighignoli, B., Kabaghe, A., Mkungudza, J., Panja, L., Raizes, E., Chitenje, M., Kampira, E., and Maida, A. (2023, January 20\u201322). HIV Drug Resistance to Dolutegravir Is Uncommon among Adults Investigated for Treatment Failure in Malawi [Abstract 53]. Proceedings of the International Workshop on HIV Drug Resistance and Treatment Strategies, Cape Town, South Africa."},{"key":"ref_134","unstructured":"Namayanja, G., Watera, C., Pais, S., Asio, J., Ssemwanga, D., Sanyu, G., Zheng, D., Zeh, C., Hackett, S., and Ntali, J. (2023, January 20\u201322). Cyclic Acquired HIV Drug Resistance to Dolutegravir among People Living with HIV in Uganda. National Remnant Samples Surveillance 2022 [Abstract 50]. Proceedings of the International Workshop on HIV Drug Resistance and Treatment Strategies, Cape Town, South Africa."},{"key":"ref_135","unstructured":"Parikh, A., Ochleng, C., Almas, S., Habib, P., Towett, J., Daud, I., Maswal, J., Owuoth, J., Singoel, V., and Bahamena, E. (2023, January 20\u201322). HIV Drug Resistance in the Dolutegravir Era: Preliminary Results from East Africa [Abstract 56]. Proceedings of the International Workshop on HIV Drug Resistance and Treatment Strategies, Cape Town, South Africa."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/3\/399\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:09:01Z","timestamp":1760105341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/3\/399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":135,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["v16030399"],"URL":"https:\/\/doi.org\/10.3390\/v16030399","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,4]]}}}